Conditions: Transplantation
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 153
Healthy volunteers: yes

Brief summary:
Pharmacokinetics, Bioavailability, Safety and Immunogenicity of Single Doses of Belatacept Administered Subcutaneously to Healthy Subjects

Detailed description:

Arms:
arm 1: Belatacept 50 mg subcutaneous (SC) injection arm 2: Belatacept 100 mg SC injection arm 3: Belatacept 125 mg SC injection arm 4: 2 SC injections of 75 mg Belatacept arm 5: 2 SC injections of 100 mg Belatacept arm 6: 2 SC injections of 125 mg Belatacept arm 7: 125 mg Belatacept intravenous (IV) injection arm 8: SC injection of placebo solution

Interventions: intervention 1: belatacept intervention 2: Placebo
Intervention descriptions: intervention 1: single dose, 116 days intervention 2: Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)

Protocol document: